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Background: Given the uncertainties regarding thyroid nodule assessment and management, physicians require
systematically and transparently developed recommendations. This systematic review assesses the quality and
consistency of the recommendations of international clinical practice guidelines (CPGs) for the diagnosis and
management of thyroid nodules and cancer to assist physicians in making appropriate recommendations.
Methods: The CPGs on the management of thyroid nodules and cancer published before June 2013 were
retrieved. All the reviewed guidelines were in English. Four reviewers independently assessed the rigor of guideline
development by using the Appraisal of Guidelines Research and Evaluation II (AGREE-II) instrument, and their
reported evidence was evaluated.
Results: Ten eligible guidelines were included: nine had been developed by professional organizations, and the
remaining guideline was endorsed by an independent regional body. Three guidelines achieved a score of greater
than 50% in all six AGREE-II domains. Guidelines scored highest on the measurement of ‘scope and purpose’
(≥61.1% for eight CPGs) and lowest on the measurement of ‘applicability’ (≤38.5% for five CPGs). The overall quality
ranged from 3.0 to 6.25 on a seven-point scale on the AGREE-II tool. Most CPG recommendations on the
management of thyroid cancer were relatively consistent. Guidelines varied regarding the indication of fine-needle
aspiration for thyroid nodules, as well as in their suggestions for postoperative radioiodine ablation.
Conclusions: Our analysis showed that the current CPGs varied in methodological quality. More effort is needed to
improve the quality of recommendations on the diagnosis and management of thyroid nodules and cancer.
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Thyroid nodules are a common clinical problem. They
are more common in women, and their incidence in-
creases with age. Epidemiologic studies have shown
the prevalence of palpable thyroid nodules in iodine-
sufficient parts of the world to be approximately 5% in
women and 1% in men [1,2]. Thyroid nodules are clinic-
ally important because they can indicate thyroid cancer,
which occurs in 5% to 15% of the population, depending
on age, sex, history of radiation exposure, family history,* Correspondence: kelvintam@h.tmu.edu.tw
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reproduction in any medium, provided the orand other factors [3,4]. Thyroid cancer is the most com-
mon malignant endocrine tumor, but represents ap-
proximately 1% of all malignancies [5]. Differentiated
thyroid cancer (DTC), which includes papillary and fol-
licular cancer, comprises the vast majority (90%) of all
thyroid cancers [6].
The standard for the diagnosis and management of
thyroid nodules and cancer is still inconclusive. Several
theories and practices, including the indication of fine-
needle aspiration (FNA), the role of the thyroid scan, the
extension of thyroid surgery for DTC, the role of cer-
vical lymph-node dissection, and the indication of ra-
dioiodine ablation (I131), are questionable. These issues
need to be clearly addressed by valid, reliable, indepen-
dent, and easily applicable clinical practice guidelinesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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guidelines containing recommendations for thyroid nod-
ules and cancer management. However, guidelines on
the same topic can conflict with each other, and the
quality and independence of the guidelines are of
concern. Therefore, clinicians require guidelines that
are systematically developed, and that provide trans-
parent estimates of the benefits and harms of inter-
ventions [7-9].
The Appraisal of Guidelines, Research, and Evaluation
(AGREE) instrument is a tool used for thoroughly
assessing the quality of guidelines [10]. The original
AGREE instrument was published in 2003 by a group
of international guideline developers and researchers,
the AGREE Collaboration. The updated version, the
AGREE-II instrument, was released in 2010 and was
funded by the Canadian Institutes of Health Research
[11]. AGREE has become the standard in the eval-
uation and development of CPGs [12,13]. Using the
AGREE-II instrument, we systematically reviewed and
assessed the quality and consistency of the recom-
mendations of CPGs on the diagnosis and manage-
ment of thyroid nodules and cancer.
Methods
Selection criteria
We selected CPGs that provided recommendations on
the diagnosis and management of thyroid nodules or
cancer. For inclusion in our study, the guidelines were
required to (1) have published in English, and (2) exam-
ine all subgroups of the population to ensure that the
CPGs catered for the needs of those with comorbidities
in various settings. When more than one set of guide-
lines was produced by the same professional body, only
the most recently issued was considered. We excluded
guidelines that (1) focused exclusively on thyroid disease
among special groups (for example, anaplastic thyroid
cancer, pregnant women or children); (2) focused en-
tirely on a unique technique, such as the procedure
guideline for radioiodine therapy; (3) concentrated on a
non-nodular disease, such as thyroid dysfunction; (4)
contained recommendations for other diseases, such as
neuroendocrine tumors or head and neck cancer; or (5)
reported non-original recommendations (referring to
other sets of guidelines).
Search strategy and guideline selection
Two reviewers (K-WT and T-WH) searched for relevant
studies using keyword searches of the following elec-
tronic databases: MEDLINE, EMBASE, CINAHL, the
National Guideline Clearinghouse, the National Institute
for Health and Clinical Excellence, the Scottish Intercol-
legiate Guidelines Network (SIGN), and the Guidelines
International Network (G-I-N) International GuidelineLibrary. The following terms and Boolean operators
were used in MeSH and free-text searches: thyroid, can-
cer OR carcinoma OR neoplasm, nodule OR mass OR
tumor, and guidelines OR recommendations. The ‘re-
lated articles’ facility in PubMed was used to broaden
the search. The last search was performed in June 2013.
Recommendation extraction and analysis
Two reviewers (K-WT and T-WH) independently ex-
tracted the details of the guidelines pertaining to the
CPG characteristics (for example, country or region, year
of dissemination, development team, and funding or-
ganization), the goals of the guidelines, the target popu-
lation and audience, the recommendations related to the
diagnosis of thyroid nodules, the recommendations re-
lated to the management of thyroid nodules and cancer,
and the evaluation of options for postoperative follow-
up. The individually recorded decisions of two reviewers
were compared, and any disagreement was resolved
based on the evaluation of a third reviewer (J-HL).
We constructed a table to compare the recommenda-
tions from the selected guidelines. The table was divided
into the following sections and items, based on the types
of clinical practices that focus on thyroid nodules and
cancer: (1) diagnosis: an indication of FNA, the role of
routine serum calcitonin, and an indication of a thyroid
scan; (2) treatment: an indication of total thyroidectomy
for DTC, and the role of cervical lymph node dissection
in node-negative patients; and (3) postoperative care: an
indication of I131 ablation, and a target level of thyroid-
stimulating hormone (TSH) suppression therapy.
Guideline quality assessment
Four investigators (K-WT, T-WH, J-HL and M-YW) in-
dependently appraised all the selected guidelines by
using the AGREE-II instrument [10]. AGREE-II consists
of 23 key items organized into 6 domains: (1) ‘scope and
purpose’, (2) ‘stakeholder involvement’, (3) ‘rigor of devel-
opment’, (4) ‘clarity and presentation’, (5) ‘applicability’,
and (6) ‘editorial independence’. Each domain captured a
separate dimension of the guideline quality with a seven-
point scale (from 7 (strongly agree) down to 1 (strongly
disagree)). For each reviewer, AGREE-II scores were calcu-
lated as a percentage by using the sum of the seven-point
scale and the maximum possible score (range 0% to
100%). Item scores were discussed by the four reviewers,
and large scoring discrepancies (defined as ≤3 points dif-
ference in the score assigned by the appraisers to the same
item) were resolved by consensus. We considered satisfac-
tory any guideline that scored at least 50% in all six do-
mains, as defined by AGREE-II. Upon completing the 23
items, each reviewer provided an overall assessment of the
guideline. We compared the mean values of each of the
six domain scores and the overall scores obtained by the
Huang et al. BMC Medicine 2013, 11:191 Page 3 of 9
http://www.biomedcentral.com/1741-7015/11/191four reviewers to evaluate the possible risk of bias and the
recommendation for future use for each CPG appraised.
Results
Literature search
The flowchart in Figure 1 shows the process by which
we screened and selected the guidelines. Our initial search
yielded 1,203 citations, of which 1,051 were deemed ineli-
gible by screening their titles and abstracts, and 62 were
excluded due to irrelevant topic. This left 90 eligible stud-
ies. Of these, 79 reports were excluded from our final ana-
lysis for the following reasons: 17 were non-English
guidelines, 2 were concentrated on non-thyroid cancer, 36
were the procedure guidelines, 12 guidelines were not the
most recent version, 2 being duplicate publication,
and 11 were the comment of original guidelines. The
remaining ten eligible guidelines were included in our
analysis [14-23].
Characteristics of the guidelines
Table 1 presents a summary of the characteristics of the
selected guidelines. The ten guidelines were published
between 2000 and 2013. Of the ten guidelines, four were
new [19,20,22,23], and the rest were updates. Of the
selected guidelines, 3 were developed in multiple
countries: the Latin American Thyroid Society (LATS)
used the guidelines from 13 Latin American countriesSearch for potentially relevant studies (
Guidelines retrieved for further
evaluation (n = 90)
Included guidelines (n = 10)
Studies identified using the MEDLINE
Guideline Clearinghouse, NICE, SIGN
Library databases (n = 1203)
Figure 1 Flowchart of the selected clinical practice guidelines.[20], the European Society for Medical Oncology (ESMO)
was approved in Europe [17], and American Association
of Clinical Endocrinologists, Associazione Medici Endo-
crinologi, and European Thyroid Association (AACE/
AME/ETA) was contributed by the USA and Europe [14].
The remaining CPGs were conducted in the USA [15,21],
the UK [16,22], Germany [18], The Netherlands [19], and
Spain [23]. Nine guidelines were produced by independent
professional scientific organizations, and the remaining
guideline was developed with the endorsement of a re-
gional independent body [22]. Five CPGs were funded by
independently professional organizations [14-16,19,21],
and the remainder did not disclose a funding source.
Appraisal of guidelines
With the exception of the ESMO and Spanish Society of
Medical Oncology (SEOM) CPGs [17,23], all the selected
guidelines stated the methods used in the literature
search, the quality of the evidence, and the strengths of
the recommendations reported. Table 2 presents the do-
main scores (%) for the ten CPGs that were assessed
using the AGREE-II instrument. Three of the selected
guidelines performed satisfactorily, achieving a score
of greater than 50% in all six AGREE-II domains
[16,19,21]. The guidelines generally received the lowest
scores for domain 5, ‘applicability’, among all six AGREE-II
domains (≤38.5% for five CPGs). Guidelines scoredn =152)
Guidelines excluded 
Non English (n = 17)
Non-thyroid cancer (n = 2)
Procedure guidelines (n = 36)
Non-original guidelines (n = 11)
Not most recent version (n=12)
Duplicate publication (n=2)
, EMBASE, CINAHL, National 
, and GIN International Guideline 
Studies excluded
Irrelevant topic (n=62)
Studies excluded after reading 
titles and abstracts (n =1051)
Table 1 Characteristics of the thyroid nodule management guidelines included in the study
Guidelines
(Year)
Organization Country or region Level of development Status Funding
AACE/AME/
ETA (2010)
American Association of Clinical
Endocrinologists, Associazione




Professional organization Updated American Association
of Clinical Endocrinologists
ATA (2009) American Thyroid Association USA Professional organization Updated American Thyroid Association
BTA (2007) British Thyroid Association, and Royal
College of Physicians
UK Professional organization Updated British Thyroid Association
ESMO (2012) European Society for Medical Oncology Europe Professional organization Updated Not available
GAES (2013) German Association of Endocrine
Surgeons
Germany Professional organization Updated Not available
IKNL (2007) Dutch Endocrine Society, and Dutch
Society of Nuclear Medicine
The Netherlands Professional organization New Dutch Society of
Medical Specialists
LATS (2009) Latin American Thyroid Society Latin America Professional organization New Not available
NCCN (2013) National Comprehensive Cancer Network USA Professional organization Updated NCCN Foundation
NCN (2000) Northern Cancer Network UK Regional independent
body
New Not available
SEOM (2011) Spanish Society of Medical Oncology Spain Professional organization New Not available
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http://www.biomedcentral.com/1741-7015/11/191highest in domain 1 (≥61.1% for eight CPGs). The British
Thyroid Association (BTA) and Dutch Endocrine Society/
Dutch Society of Nuclear Medicine (IKNL) guidelines
scored the highest on domain 1 (87.5% and 87.5%) and
domain 2 (76.4% and 75%) [16,19]. Moreover, the IKNL
guideline scored the highest for domain 3 (88.5%) [19].
The National Comprehensive Cancer Network (NCCN)
guideline scored the highest for domain 4 (81.9%) and do-
main 6 (85.4%) [21]. Domain 5 scored consistently low
across the CPGs.
Table 3 details the mean scores for the 23 items and
the overall mean scores for each domain from the 10
guidelines evaluated as assessed with AGREE-II, by aver-
aging the scores from each of the 4 investigators. The
overall quality of the CPGs ranged from 3.00 ± 0.00 to
6.25 ± 0.50 of a possible 7 on the AGREE-II tool. In
general, the lowest mean scores were for item 5 (range
1.75 ± 0.50 to 4.25 ± 1.71) and item 21 (range 2.0 ± 0.0







Domain 1: scope and purpose 76.4 84.7 87.5
Domain 2: stakeholder involvement 65.2 72.2 76.4
Domain 3: rigor of development 62.5 62.0 66.1
Domain 4: clarity of presentation 77.8 70.8 69.4
Domain 5: applicability 38.5 42.7 56.3
Domain 6: editorial independence 79.2 81.3 75
Guideline group abbreviations are as follows: AACE/AME/ETA American Association
Thyroid Association, ATA American Thyroid Association, BTA British Thyroid Associat
Oncology, GAES German Association of Endocrine Surgeons, IKNL Dutch Endocrine
Society, NCCN National Comprehensive Cancer Network, NCN Northern Cancer Netwguidelines seldom provided the views or preferences of
the target population or the monitoring or auditing cri-
teria of the key recommendations.
Clinical practice guideline recommendations
Recommendations for the diagnosis and management of
thyroid nodules and cancer extracted from these guide-
lines are shown in Table 4. Regarding the diagnostic pro-
cedures, all guidelines advocated thyroid sonography. In
addition, a measurement of TSH and free thyroxine
levels should be performed in all patients. A routine
measurement of serum thyroidglobulin (Tg) for the ini-
tial evaluation of thyroid nodules is not recommended.
However, although all the guidelines supported FNA as
the procedure of choice in the evaluation of solid thyroid
nodules, the CPGs define various nodular sizes as indi-
cations for FNA. The German Association of Endocrine
Surgeons (GAES), IKNL, and Northern Cancer Network















33.3 61.1 87.5 79.2 79.2 68.1 40.2
22.2 54.2 75 44.4 69.4 51.4 26.4
21.4 58.9 88.5 45.8 58.3 36.4 16.1
38.9 63.9 73.6 54.2 81.9 56.9 45.8
22.9 35.4 63.5 40.6 57.2 29.2 21.9
39.6 45.8 79.2 52.1 85.4 29.2 33.3
of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European
ion and Royal College of Physicians, ESMO European Society for Medical
Society and Dutch Society of Nuclear Medicine, LATS Latin American Thyroid
ork and SEOM Spanish Society of Medical Oncology.
Table 3 Quality of the thyroid nodule/cancer clinical practice guidelines for the six domains of the AGREE-II Instrument






















1 6 (0) 6.25 (0.5) 6.5 (0.58) 3.5 (0.58) 5 (0.82) 6.5 (0.58) 6 (0) 6.25 (0.5) 6 (0) 3.5 (0.58)
2 5.75 (0.5) 6.5 (0.58) 6.25 (0.96) 3.25 (0.96) 5 (0.50) 6.5 (0.58) 6 (0) 5.5 (0.58) 4.25 (0.5) 3.5 (0.58)
3 6 (0.82) 5.5 (1.29) 6 (1.41) 2.25 (1.26) 4.25 (0.96) 5.75 (1.5) 5.25 (0.96) 5.5 (1.29) 5 (0.82) 3.25 (0.5)
D2
4 5.5 (0.58) 6.25 (0.5) 6.25 (0.5) 2.5 (1.29) 5 (1.15) 7 (0) 4 (1.41) 6.75 (0.5) 5.25 (0.5) 2.75 (0.5)
5 3.25 (0.96) 3.75 (1.71) 4.25 (1.71) 1.75 (0.50) 2.75 (0.96) 3 (1.41) 1.75 (0.50) 2.5 (0.58) 1.75 (0.5) 2 (0)
6 6 (0) 6 (0.82) 6.25 (0.5) 2.75 (0.50) 5 (0) 6.5 (0.58) 5.25 (0.50) 6.25 (0.5) 5.25 (0.96) 3 (0.82)
D3
7 6 (0.82) 3.75 (0.96) 4.5 (1.29) 1.25 (0.50) 5 (0.82) 6.75 (0.50) 3.75 (0.96) 3.5 (0.58) 2.75 (0.50) 1.75 (0.50)
8 4 (0.82) 5.5 (1.29) 4 (0.82) 1 (0) 5.25 (0.50) 6.75 (0.50) 3 (0.82) 4.25 (0.50) 3.25 (0.50) 1.25 (0.50)
9 4.5 (1.73) 4 (1.15) 4.75 (1.50) 1.5 (0.58) 3.5 (1.29) 6.25 (0.50) 3 (0.82) 4.5 (1.29) 3.25 (0.50) 1.75 (0.50)
10 5.25 (0.96) 4.75 (0.5) 5 (1.41) 3 (0) 5.75 (0.50) 6.5 (0.58) 4.25 (1.50) 5 (0.82) 3.75 (1.50) 2 (0)
11 4.25 (1.50) 4.25 (0.96) 4.5 (1.29) 2.75 (0.96) 4.5 (0.58) 6.25 (0.50) 3.75 (1.50) 5.75 (0.50) 3.25 (1.26) 2.25 (0.50)
12 6 (0) 5.25 (1.71) 6.25 (0.96) 4.75 (0.50) 4.5 (1.00) 6.5 (0.58) 2.75 (0.50) 4 (0.82) 2.5 (1.00) 2.75 (0.96)
13 4 (1.15) 5.5 (0.58) 5.75 (0.50) 2 (0) 4 (1.41) 5.75 (0.50) 5.25 (0.50) 4 (1.15) 4.5 (1.29) 2 (0)
14 4 (1.83) 4.75 (0.96) 5 (0.82) 2 (0) 3.75 (0.50) 5.75 (0.50) 4.25 (1.50) 5 (1.41) 2.25 (0.50) 2 (0)
D4
15 6 (0.82) 6 (0) 6 (0) 3.75 (0.96) 5 (0) 6.25 (0.50) 4.5 (0.58) 6.25 (0.50) 4.5 (0.58) 4 (0)
16 5 (1.83) 3.75 (0.96) 3.75 (0.96) 3 (0.82) 3.75 (0.96) 4.5 (1.73) 3.75 (1.50) 5.5 (0.58) 4 (1.15) 3.25 (0.96)
17 6 (0.82) 6 (0) 5.75 (0.50) 3.75 (0.50) 6 (0) 6.25 (0.50) 4.5 (0.58) 6 (0) 4.75 (0.50) 4 (0)
D5
18 3 (0.82) 3.25 (0.50) 4.5 (0.58) 2 (0) 2.75 (1.26) 5.25 (0.50) 3 (0) 4 (0.82) 2.75 (0.50) 2 (0)
19 4.25 (1.50) 4 (1.41) 6 (0.82) 2.75 (0.96) 4.25 (1.50) 6 (0) 4.25 (1.50) 5.75 (0.50) 3.5 (1.29) 3 (1.15)
20 3.25 (1.71) 3.75 (1.26) 3.25 (1.26) 2 (0) 3 (1.41) 4.25 (1.26) 3.5 (1.29) 4 (0.82) 2.25 (0.50) 2.25 (0.50)
21 2.75 (0.96) 3.25 (1.50) 3.75 (1.71) 2.75 (1.50) 2.5 (1.00) 3.75 (0.96) 3 (1.15) 4 (0.82) 2.5 (1.00) 2 (0)
D6
22 5 (1.15) 6 (0.82) 5.5 (1.73) 3 (0.82) 5.25 (0.96) 6 (0) 4 (1.41) 5.75 (0.50) 1.75 (0.50) 4.5 (1.29)
23 6.5 (0.58) 5.75 (1.89) 5.5 (1.73) 3.75 (0.96) 2.25 (0.50) 5.5 (1.29) 4.25 (1.50) 6.5 (0.58) 3.75 (0.96) 1.5 (0.58)
Overall 5.75 (0.50) 6 (0) 6.25 (0.50) 3.75 (0.96) 5 (0) 6.25 (0.50) 4.25 (0.50) 5.5 (0.58) 4.25 (0.96) 3 (0)
Domain areas are as follows: D1, scope and purpose; D2, stakeholder involvement; D3, rigor of involvement; D4, clarity of presentation; D5, applicability; D6,
editorial independence. All the 23 items of the Appraisal of Guidelines Research and Evaluation II (AGREE-II) instrument are rated on a seven-point scale from 7
(strongly agree) down to 1 (strongly disagree). Overall: the numbers in the overall row represent the averages of the scoring performed by four assessors.
Guideline group abbreviations are as follows: AACE/AME/ETA American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi and European
Thyroid Association, ATA American Thyroid Association, BTA British Thyroid Association and Royal College of Physicians, ESMO European Society for Medical
Oncology, GAES German Association of Endocrine Surgeons, IKNL Dutch Endocrine Society and Dutch Society of Nuclear Medicine, LATS Latin American Thyroid
Society, NCCN National Comprehensive Cancer Network, NCN Northern Cancer Network and SEOM Spanish Society of Medical Oncology.
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http://www.biomedcentral.com/1741-7015/11/191performed in all nodules [18,19,22], two CPGs recom-
mend that the indication of FNA must be performed in
nodules >0.5 cm in diameter [15,16], and the other three
CPGs suggest that FNA cytology is needed when the
thyroid nodule is bigger than 1 cm in the absence of
clinical suspicion [14,17,23]. In the 2013 version of the
NCCN guidelines, the threshold for FNA is a solid
thyroid nodule >1.5 cm, if no suspicious sonographic
features are present [21]. For laboratory evaluation, fourCPGs recommend routine serum calcitonin, particularly
before surgery for nodular thyroid disease [17-19,23].
Four guidelines suggest a serum calcitonin assay as an
optional test [14,20-22], but the American Thyroid Asso-
ciation (ATA) guidelines cannot recommend or discour-
age the routine measurement of serum calcitonin, because
of insufficient evidence [15]. For radionuclide scanning,
three guidelines mentioned thyroid scintigraphy in a single
thyroid nodule with a low TSH level [14,15,21], and the
Table 4 Recommendations stated in the ten clinical practice guidelines
Recommendations AACE/AME/ETA
(2010)







n >1 cm n >0.5 cm n >0.5 cm n >1 cm All nodules All nodules N/A n >1.5 cm All
nodules
n >1 cm
Routine serum calcitonin Optional NR N/A R R R Optional Optional Optional R










N/A n >1 cm n >1 cm n >1 cm n >1 cm n >1 cm All sizes n >4 cm n >1 cm n >4 cm
Cervical lymph node dissection
(node negative)
N/A n >4 cm n >4 cm/male/
age >45 years
Optional Optional N/A n >4 cm Optional Unclear Optional
Postoperative care












n >1 cm High-risk
patients
Target level of TSH suppression
therapy (mU/L)
High risk N/A <0.1 <0.1 <0.1 N/A <0.1 <0.1 <0.1 0.01 to 0.1 <0.1




Guideline group abbreviations are as follows: AACE/AME/ETA American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi and European Thyroid Association, ATA American Thyroid Association,
BTA British Thyroid Association and Royal College of Physicians, ESMO European Society for Medical Oncology, GAES German Association of Endocrine Surgeons, IKNL Dutch Endocrine Society and Dutch Society of
Nuclear Medicine, LATS Latin American Thyroid Society, NCCN National Comprehensive Cancer Network, NCN Northern Cancer Network and SEOM Spanish Society of Medical Oncology.
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http://www.biomedcentral.com/1741-7015/11/191GAES CPGs recommend thyroid scintigraphy before the
planning and execution of an operation [18].
Concerning thyroid surgery for DTC, patients with
node-negative cancer 1 cm in diameter or more should
be treated with total or near-total thyroidectomy, except
where contraindications prevent this surgery [15-19,22].
However, the NCCN and SEOM CPGs recommend total
or subtotal thyroidectomy in tumors >4 cm in diameter
[21,23]. In contrast, the LATS guidelines recommend
total thyroidectomy for DTC, regardless of tumor size
[20]. An additional surgical consideration is cervical
lymph node dissection for patients with DTC. Three
CPGs recommend that prophylactic central-compart-
ment neck dissection may be performed in patients who
present with a DTC with clinically uninvolved central-
neck lymph nodes, especially for advanced primary tu-
mors (nodule >4 cm) [15,16,20].
Recommendations for the postoperative care of DTC
are varied. First, radioiodine ablation is recommended
for all high-risk patients, as determined from the pres-
ence of metastases, incomplete excision, gross extrathy-
roidal extension of the tumor regardless of tumor size,
or a primary tumor >4 cm, even in the absence of other
higher-risk factors [15]. However, the NCN guidelines
mention that routine postoperative I131 ablation of thy-
roid remnants has been shown to reduce local recur-
rence and improve patient survival when they have
tumors more than 1 cm in diameter [22]. Moreover, the
NCCN guidelines recommend that I131 ablation be
performed in patients with thyroglobulin >1 ng/ml [21].
Second, all CPGs emphasized the need for TSH suppres-
sion therapy following DTC surgery. However, the target
levels of the TSH varied across the guidelines. Initial
TSH suppression to below 0.1 mU/L is recommended
for high-risk patients [15-17,19-21,23], whereas NCN
guidelines suggest the maintenance of the TSH at 0.01
to 0.1 mU/L [22]. Moreover, CPG recommendations
were inconsistent regarding the maintenance of the TSH
in low-risk patients.
Discussion
This study assessed the quality and consistency of the
recommendations of international CPGs on the diagno-
sis and management of thyroid nodules and cancer to
assist physicians in considering the appropriate recom-
mendations. We identified ten guidelines involving thy-
roid nodules and cancer management, three of which
had been published between 2000 and 2007 [16,19,22].
As a general rule, CPGs should be reassessed for validity
every 3 years [24,25]. Therefore, one of the CPGs re-
viewed here are likely to be outdated because they have
not been updated in over 10 years [25]. A distinct var-
iation in the applicability and transparency of funding
sources was found among the guidelines. After applyingthe AGREE-II instrument to the ten guidelines, we
found that guidelines developed by the BTA [16], the
IKNL [19], and the NCCN scored above 50% in all six
domains [21]. Moreover, the view of the target popu-
lation (domain 5) on guideline development was in-
adequate in all ten guidelines. We found differences
among guidelines with respect to the indication of FNA
in low-suspicion nodules, the routine measurement of
serum calcitonin, and the role of cervical lymph node
dissection in node-negative patients.
The application of AGREE-II allows for an evaluation
of the various aspects of guidelines. We measured the
development methods of the guidelines by using the
AGREE-II instrument, based on the rationale that a high
methodological quality is fundamental for the integrity,
reproducibility, and transparency of guidelines. Our
study showed that the methodological quality of the
guidelines was optimal for ‘scope and purpose’ and ‘cla-
rity and presentation’, but received the lowest scores for
‘applicability’. Most guidelines lacked explicit statements
on whether the patients’ views and preferences had been
sought (item 5), whether the various options for ma-
nagement of the condition were clearly presented
(item 16), whether the potential cost implications of ap-
plying the recommendations were considered (item 20),
and on key review criteria for monitoring and/or auditing
purposes (item 21). Although the AGREE-II instrument
provides six independent scores for six corresponding as-
pects of the guidelines, we believe that clinicians would be
more concerned about the ‘rigor of development’. How-
ever, the quality of ‘applicability’ domain also plays a
critical role in implementation of the guideline. For a
guideline to be effective, it should provide advice as to
how the recommendations can be implemented, it should
present a discussion of the potential impact of recommen-
dations on resources, and it requires clearly defined cri-
teria derived from the key recommendations. Therefore,
we recommend that clinicians rely preferentially on the
guidelines that performed better regarding the ‘applica-
bility’ domain [16,19,21].
The AGREE-II instrument is used to establish a uni-
versal standard for the rigor and transparency of guide-
line development, and to suggest how to improve
existing guidelines [11]. However, some limitations exist.
One serious limitation concerns conflicts of interest.
The AGREE-II instrument advocates that guidelines al-
ways report clearly, irrespective of whether conflicts
exist, but several of the guidelines lacked statements
about conflicts of interest. The use of a guideline-
adaptation framework such as ADAPTE should be con-
sidered to develop high-quality CPGs in the future [26].
In general, the recommendations of the CPGs on
the diagnosis, management, and postoperative care of
thyroid nodules and cancer were consistent, despite
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velopment’. All guidelines advocated thyroid sonog-
raphy, as well as measured the TSH and free thyroxine
levels in all patients. However, no firm recommendations
were made for the routine assessment of serum calcitonin
and the indication of thyroid scintigraphy. Similarly, major
differences across the CPGs were related to the indication
of radioiodine ablation and the optimal level of TSH sup-
pression therapy in patients with DTC (Table 4). Such sit-
uations revealed that, even when CPG developers claimed
to have paired their grade of recommendations with the
level of evidence, recommendations were not graded or
were inconsistent. This variation may be related to the de-
velopers’ search strategy, the process of selecting scientific
evidence, and the way the recommendations had been for-
mulated [27,28].
In prospective trials, conclusions regarding the optimal
selection of treatments must be based on retrospective
analysis and the consensus of expert opinions [15-17,29].
Several CPGs recommend total thyroidectomy if the pri-
mary tumor is at least 1 cm in diameter or if extra-
thyroidal extension or metastases are present [15-18,22],
but some guidelines advise that total thyroidectomy may
be performed in patients with large tumors (>4 cm) in
the absence of clinical suspicion [21,23]. Whereas some
CPGs recommend considering routine central-neck dis-
section for most patients with papillary thyroid cancer
[15,16,20], the guidelines from the NCCN recommend
only central-neck dissection in the presence of grossly
positive metastasis [16,19,21].
The strengths of our review included a comprehensive
search for eligible guidelines, the systemic and explicit
application of eligibility criteria, the careful consider-
ation of guideline quality by using the AGREE-II instru-
ment, and a rigorous analytical approach. Therefore, this
study can be of additional value to already available
guideline compendia and libraries such as the National
Guideline Clearinghouse and the National Institute for
Health and Clinical Excellence because these libraries
depend on submissions from guideline organizations.
However, several limitations could have biased our
study. First, only CPGs written in English were included,
and guidelines written entirely in other languages might
have been overlooked. Second, CPGs that focus on non-
DTC such as medullary thyroid cancer or unique tech-
niques such as procedural guidelines for radioiodine
therapy were excluded from our study. Third, the
AGREE-II instrument is used to evaluate the guideline
as a whole, and is not intended for specific, individual
recommendations. However, a global appraisal on a
guideline’s construction process may reflect the strength
of the individual recommendations to an extent. Finally,
we used only the AGREE-II instrument in evaluating the
quality of the guidelines. Other instruments such as thefour-item Global Rating Scale (GRS) may also play a role
in guideline assessment [30]. Although the GRS is less
sensitive than AGREE-II in detecting differences in
guideline quality, its items did predict outcome measures
related to guideline adoption.
Conclusions
In summary, the results of our study revealed that
current CPGs varied in methodological quality, and in-
creased efforts are required to improve the quality of
recommendations on the diagnosis and management of
thyroid nodules and cancer. We therefore encourage cli-
nicians to use the guidelines from this review with
higher AGREE-II rigor scores for managing patients with
thyroid nodules or cancer.
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